2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. IGF-1R

IGF-1R

Insulin-like growth factor-1 receptor

IGF-1R

Related Products

PDF 0.48 MB

IGF-1R (Insulin-like growth factor 1 receptor), a receptor tyrosine kinase, is activated upon binding to the ligands IGF-1 or IGF-2 leading to cell growth, survival and migration of both normal and cancerous cells.

IGF-1R can initiate the activation of the PI3K/AKT/mTOR signaling and Ras/Raf/MEK/MAPK pathways resulting in the activation of multiple transcription factors such as ELK-1, CREB and AP-1 to modulate cell proliferation, survival, differentiation, motility, invasion and angiogenesis. IGF-1R overexpression or increased IGF-1R kinase activity is associated with a broad range of human cancers and therefore the IGF-1R is widely considered as a very promising target for cancer treatment.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99218
    Robatumumab
    		Inhibitor 99.90%
    Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.
    Robatumumab
  • HY-P991042
    Anti-IGFBP2 Antibody (M14)
    		Antagonist ≥99.0%
    Anti-IGFBP2 Antibody (M14) is an human anti-IGFBP2 monoclonal inhibitory antibody, which binds IGFBP2 with high affinity and blocks its binding with IGF1. Anti-IGFBP2 Antibody (M14) inhibits human endothelial cell recruitment, thus blocks the tumor progression of human metastatic cancer.
    Anti-IGFBP2 Antibody (M14)
  • HY-P99867
    Dusigitumab
    Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1.
    Dusigitumab
  • HY-135436
    AG 538
    		Inhibitor 99.80%
    AG 538 is a potent, competitive inhibitor of IGF-1 receptor kinase, with an IC50 of 400 nM.
    AG 538
  • HY-135680
    I-OMe-Tyrphostin AG 538
    		Inhibitor 98.03%
    I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells.?I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50?of 1 μM.
    I-OMe-Tyrphostin AG 538
  • HY-156914
    IGF-1R/SRC-IN-1
    		Inhibitor 99.86%
    IGF-1R/SRC-IN-1 (Compound 3b) is an inhibitor for IGF-1R (IC50 is 63 μM) and SRC.
    IGF-1R/SRC-IN-1
  • HY-B0794
    AZ7550
    		Inhibitor
    AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
    AZ7550
  • HY-108905
    Mecasermin
    Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies.
    Mecasermin
  • HY-125102
    AZ12253801
    		Inhibitor
    AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC50 of 17 nmol/L. The IC50 for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.
    AZ12253801
  • HY-135749
    BN201
    		Activator 99.89%
    BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes (EC50 of 6.3 μM) in vitro, and the myelination of new axons (EC50 of 16.6 μM). BN201 is able to cross the blood-brain barrier by active transport and activate pathways (IGF-1 pathway) associated with the response to stress and neuron survival. BN201 has potently neuroprotective effects.
    BN201
  • HY-15656S
    Ceritinib-d7
    		Inhibitor 98.00%
    Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.
    Ceritinib-d<sub>7</sub>
  • HY-161618
    MJ04
    		Inhibitor 98.08%
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg).
    MJ04
  • HY-B0794A
    AZ7550 hydrochloride
    		Inhibitor 98.66%
    AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
    AZ7550 hydrochloride
  • HY-P99672
    Istiratumab
    		Inhibitor 98.45%
    Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers.
    Istiratumab
  • HY-B0794S
    AZ7550-d5
    		Inhibitor
    AZ7550-d5 is the deuterium labeled AZ7550?(HY-B0794). AZ7550, an active metabolite of Osimtinib (AZD9291; HY-15772), inhibits the activity of?IGF1R?with an?IC50?of 1.6 μM.
    AZ7550-d<sub>5</sub>
  • HY-15494R
    Picropodophyllin (Standard)
    		Inhibitor
    Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin (Standard)
  • HY-21291
    SU-4313
    		Modulator 99.31%
    SU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC50s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation.
    SU-4313
  • HY-P990966
    Redalsomatropin alfa
    Redalsomatropin alfa (JR-142) is a recombinant long-acting growth hormone. Redalsomatropin alfa extends its half-life through fusion with modified serum albumin. Redalsomatropin alfa is well-tolerated and can maintain IGF-1 levels. Redalsomatropin alfa can be used in research related to growth hormone deficiency.
    Redalsomatropin alfa
  • HY-50866B
    NVP-AEW541 dihydrochloride
    		Inhibitor
    NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity.
    NVP-AEW541 dihydrochloride
  • HY-B0794BR
    AZ7550 Mesylate (Standard)
    		Inhibitor
    AZ7550 Mesylate (Standard) is the analytical standard of AZ7550 Mesylate. This product is intended for research and analytical applications. AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
    AZ7550 Mesylate (Standard)
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity